                           ˿µϣ2011417գ

11.04.16ûи
11.04.17, ӡҽҩ⡱񻰵
11.04.17, ӡٴĽФЧ
11.04.17, ʸФǷɹ޷ȷ
11.04.17, ʸФФϷ仡ˡʧķ仡
11.04.17, ͬϺɭɲ𣿡
11.04.17, ١ٱ񲿳ְVSɭг
11.04.17, KENֻʵΪʲôɡг
11.04.17, 廪塶廪ѧĲӦɭȷϵϮ
11.04.17, ط硶츸³δѡոġõ誽ڵַӡ
11.04.17, ֢ߡңΰ֮ӣ
11.04.17, moonzyԡ˼ƫѧΥݲ𣿡
11.04.17, ŹҫҹҲĲг
11.04.17, ҩעš ŷޣ
11.04.17, 걨Фս

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

             ҽҩ⡱񻰵

                       ӡ

ýһֱҽҩڹӭϵйҽ
ѧߵĴţξҩˣ˵öˣ
Ϊ档˻Ԥҽڹ˥ͬʱڹõԺ˵
й˷Ҫȥѧҽơ

һҹҩܱ˳ŷгıúܶ˴
⡣ƣ2004ŷ˳̨ġͳֲҩעָ涨ֲҩ
ҵ2011430ǰעᣬŷ˾ۺʹá
һ޽ҩٲò˳ŷ˵ΪȻйһ
Щҩҵŷ˵ݽϣڶԭ򣬽Ŀǰûһҵͨ
ŷˡͳֲҩעָļעᡣ

򱨵͸¶һЩϢ֪ҽҩŷ޵ʵξΡ
ŷ˵Ĺ涨һֲҩĵעɱԼΪ100Ԫҡע
ִҩﶯԪзɱȿԺԲƣڵҩҵ
ȻΪעɱ߰ûһԸȥǮɴ˿֪ҩŷ޵
۶ʵСÿ

ŷ˵Ĺ涨Դͳҩһ棬Ҫҩһаȫ͹Ч
ԣֻҪ֮ǰҪ30ҩʷаŷ˵15
ʹʷˣҩҲûܴﵽ͵òٵ͵ҪΪ
ǰʹŷۣҲΪҩʹõģΪʳƷ

ҩȫ˳ŷˣûмŷ޵Ļ߻ҽ飬ûмŷ
šҽƻҪΪ˲ȡȴʩ˵ҽҩŷ޵ʹٵ
ԺԲƣڿп޵ıԵλʧŷ޵ҽƱ
ʵӰ졣Ҳӳһúܶй˸еʵĿǰû
ּҪõҩβɣŷҽƲſҩʧ
ԣŷ˵ܵ𺦡

ŷޣҲˡΪϿڱõҩಿţʳƷҩƷ
û׼һҩУҩΪʳƷгģ
ҪǻãгݶСҽҩҽѧϵҽΪ
䡰ҽѧһֶڣӰ컹ҽѧ

ͨ조ҽҩ⡱񻰣ֻ󵼹ˡԹ
˲лĻĲҽҲڸıҽҩĹʵλֻ
ÿѧҩЧԺͰȫԣ֤ĳҩȷٴ
пܻùʳϣй˵ĹײܵõӶΪִҽѧһ
ֶȫĹͬƸ

2011.4.13

»ÿյѶ2011.4.15

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

           ٴĽФЧ

                     ӡ

BeaumontҽԺPetersҽФϷ仡1ٴ3
ý92ʧȥãʣµ6©ȫѹʧʣ1
ߴڷ䣬ұǰöࡣ5㡢4׹ƣӦͬʱ
ĳ˨ϵɽãñǣɹ𣿲ܿ϶
(Success? Not Sure)

1ٴĽʵФЧ֪Ф
ӴġФϷ仡Уֻ
1΢ķ䣬ʧ˵ڡФϷ仡ν
ķֻѵγɵĲȶ䡣2ٴ黹ô

ФƻӭФЧ߽Ҳμдᣬƣ
һƣǻѧȷ
ʵ200912·ݾһҽԺѧ飬ǡ
޸ơѵФ

Petersҽı
http://www.icsoffice.org/Documents/Documents.aspx?FolderID=107

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ФǷɹ޷ȷ

ߣʸ

ͷźФƣ˵ĽйĻá
ΪйĳɹҪѧĽ֧š
ٿдᷢФܽᱨ档

Фġá֧šФһ
ԡţ񫡣磬20099ФǰϦФ
ơ999Լ򡱣֤
ޱ߼ʵĴţοҲ⡣

Ȼ˿ѡˡBeaumontҽԺФ鸺
K. Petersڽ2³ڹʧѧᷢĽϣй
Ĺؼֽ¡

1. 9δμãǸ⡱

Фơйɹһ10Ϊ
ٴоȷ淶Ͻɿй˵Ǹ⡱ Beaumont
ҽԺٴҲ˵йϸĻǸս
֤չıҪԡʵϣФ15˻ߣҲ
ʧһ淶Ͻɿе9߾Ȼʧ
ȷʵǸ⡱δἰʧԭǻЧ
Ըڡ

2. 5/7ֱܸơ4/7׹ܸơ6/76/9
66%ٴиơ

ФԴҽԺġԺʿϣФ걨Ժʿ
Фʼ֤ԲеĴʿɲǡơimprove
(void)ҲǱᵽĸߡżͨʶֻ
ߡǡСָȫԿء
磺ĿǰȫԿ24֢״Ը5޸ı2Ч
93.5%Ф2002귢31˻߽磺7
޷ͻ4ÿܣʧʧ6߷ͻ
ȫ1һָɿʣ𽥼22+/-15mlӯ
ʧʧ˹仡ܰȫЧԼ輹Ĥ´Сʧ 
Ф2003귢13ѻ߽

ҽģΪʲôοһФӢеôأ磺
complete bladder function restoration ׹ȫָ
regained total control of the bladder ðȫƹܣ
successful recovery of bladder function ׹ܳɹָ
almost normal storage and synergic voiding 洢Эͬ򼸺

gained satisfactory bladder control and continence İ
׿ƹܺͿ
regained bladder control ð׿ƹܣ

3. ʧԳ⡱6/7©ȫѹʧ

Աһ£һФ2003걨棬13ѻ10
ʧʧÿܡ

4. ꣬ʣһߴڷ䣬Զǰ

˾ķ֣ƷФϷ仡ۻ
ФФϷ仡ˡʧķ
仡

5. 7е4(5)ٵ򡱣һ⣬ȫ迹ҩ


赼迹ҩɹǺŪФ˵ȫһ
⣬ǳ򵥣ǳSTUPID⣺DETROPENർӦá
˵ҽôͳҩӵǧФ!ˣ
һмеۣҪɹͱֹֹͣͣҩ
ͣ˵ͣҩ͡ɹˡФ׷ι
ѧ־ԡФɡ

6. ȷе֫ķգر1/9´

Фóһʮǰڼѻ״ףͼ֤й
ФܺߵĲмǼѱɵġôФν
ѾȷФ֢ļý屨
98֢֫֫˳ʱ
Ʋʹ7ǿָǰˮƽһ´޷ָ
ߵĸϷŮڶ˫ޣThe day 
after her surgery, we tried to get our daughter up to walk and her 
legs dangled like a rag doll.ֵĲ֢йܺ
żʣôǼѱɵ𽥻չ֢״

1/9´һӦй2000ܺ200
´οиԵƶɵĲм

7. Ƿɹ޷ȷζٴɹһѵս

һУ棺о֮
ζɹʱΪɹ־֮һķ仡ʧˣȻ͸
ˡBeaumontҽԺ2006׿ʼѾˣȻ㲻ô
ɹٴʷЦɡΪʲôȥԼ
ô趨ĿģΪʲôȥФԴҽԺ򿴿Ф
ôɹģٲãΪʲôʷعˣ봫ͳ
˩ϵɽȱ޲бȽϣ޷ǣûдﵽ
ԼĿ꣬޷ФġɹᲢۣȲϴͳ

ͬרһ״սˣФǰĳɹʳ
85%ٴЧ루ФǰĽȻͬˣν
Ƿɹ޷ȷڵͬר˵ֱ˵֣
ʧܡ

ȻɹĶ壬ֻΪʧܡֽ
ФȻйĻáɼФйԶֹʧ
ܣǺ

8. Фʺڷչйң

ۡ˵Դķң߿ͨർʹ
ҩֹظȾ˥߼˼ƺФʺϷ
ҡۡȷ˵ЩȱԸർͿҩ
Ĺң׺ֱؽ߻ҿɾФ
ֻйķչйˡ

ǣPetersû뵽йķչйңܶ໼ҵ
ܸ𰺹ѡصǣͬû󿵸ѵ
Beaumontһ´޷ָ˾˳ʱܼƲʹ
֢֫ǿָǰˮƽйЩԴҽԺ֮
ƶԵƿѵĻߣζ֫м

0. ФΪʲôżǰдᷢ
أ

ѧ־ͨ涨ѧ־
http://www.jurology.com/content/media#embargoķǰӦѭϸ
ŷԱ֤ѧѧɣƹѧ;
һ֮ʹ󵼴ڡӱͬеļල顣

һ⵽ͬר˵Ǳá
εӲҲ̶ãФۻƷˣԤϣ
ؽ⵽ͬרҸﵽƤĳ̶ȡ

ˣФѧأҪǰԽ޴
߿дᣬ޷ָڼ޴ӻԭʼϡĿǰ޵
ͬרҶн۵£ͨԴޡ
Դﵽ﷽Ӻ˿ŪýʹڵĿġ

ҵǣѾϤĹؼֽزԭ
ļ븽ͬʱȰЩҪμФдļߣӦ
ʽͬרҵۣФһ
ĴţͻԡԸȴʽļߣɲοͬרҶФ
ٴۡͬרҶǰһйط仡
ʧȥѸۼأǽͬרҶۡ

ع
K Petters
201124 ʧѧ



[] 
[] 97ǰ
[] 137Ի֢״ޱ仯
[] 2δǰãΪӦ
[] ۺ5/7ֱܸ
[] ۺ4/7׹ܸ
[] ʧԳ
[] 6/7Ըһ
[] ɹ𣿲ȷ

굼
[] ǰȫ߾Ъ
[] 36£7е4(5)ٵ
  - һ36ǰ·Ⱦĸ俪ʼ
  - ˻ԻԾ꣬<50 cc
  - Ѳٵ
[] 1ÿ쵼һ
[] 137ޱ仯赼


ճ
[] ǰ2/9һЩ
  - ƽ27 cc
[] 366/7Ƥעһ7˿
  - ƽ156 cc
עȥδõߺ󣬴ָԺһ133ml
ԶѷФĽ
366ˣ37Ի߲עһ37
ǰһ
[] ƽ248 ccƤ
[] ƽ93 cc
עȥ򲻳37껼ߺδõߺ󣬴ָԺһ
119mlԶѷФĽоٵġʣ𽥼
22+/-15ml
[] ſʣ73%

ģʽ
[] 6/7©ȫѹʧ
[] 2/7żͨʶ
[] 1/74/7ʱ1/7ʼ

[] ǿ-2ˣ-3ˣ-2
[] ƣ-1ˣżȻ©3ˣƵ©3
[] ׳ӯУ-7ˣ-0
[] ׸оƣ-4ˣ-3

˳Ӧ(7)
[] ǰ˳Ӧֵ15.2 ml/cmH203628.4 ml/cmH20
עǰָФѲָ꡿
[] ͯ˳ӦǰС1036ȫ
    - 7.0  -> 34.3
    - 9.4  -> 21.2
    - 8.3  -> 28.4

ԴԱ򼡹Ȼ(7)
[] ǰƽ210 ccֵ200 cc עǰָФ
Ѳָ꡿
[] ƽ293 ccֵ316 cc עһ5ӡ
4˼٣ƽ253 cc
   *ͯ עףͯÿԼ15 cc
[] ǰʾ4/7ԴԱ򼡹Ȼ
[] ꣺1/7ԴԱ򼡹Ȼ*
  - һ*ȫ迹ҩ*
   *˳־Ա򼡹ȻΪ37
   עһ棬9ǰ4迹ҩȫ
迹ҩ


[] һڣ7/9ߴƤ׷䣨Ϊ̼Ƥ10 
cm/H20ѹΪ11-30 cm/H20
[] ꣬ʣһߴڷ䣬Զǰ
[] ˷䣿

¼
[] µĳڲ
[] ȶ
[] ȶ


[] СҽHolly GilmerǵŶ
[] ФҽBeaumontҽԺලGilmerҽʵʩ4Ѷͯؽ
[] ʱ֫´
[] 2ԼҺ©
[] һ꣬2/4赼Ϳҩ


[] Դ԰׺ֱٴϵشս
[] Դķң߿ͨർʹҩֹظȾ˥
߼
[] ؽָ׺ֱܵĸйФƹռ
[] ЩȱԸർͿҩĹң׺ֱؽ
߻ҿɾ
[] ڼѻȺУǵ6/966%ٴ

[] ȷе֫ķգر1/9´
[] ûзڲ¼
[] һӰİ׺ֱܣζٴɹһѵ
ս
[] ڱУѹʧȻǸ⣬ԴԱ򼡹Ȼ
ҩʹü
[] ǿΪҪжٴ飬ȷؽԴԻ
еĹ
[] ӦõȷʻȺһֱ
ԼԼ

Ӣд
CIC Clean Intermittent Catheter
CNS Central Nervous System
GRA Global Response Assessment
ISC Intermittent Self-Catheterisation
MCC Maximal Cystometric Capacity
NDO Neurogenic Detrusor Overactivity
PVR postvoid residual
UDT Urodynamic Test
UTI Urinary Tract Infection

Ӣԭġ

http://www.icsoffice.org/Documents/Documents.aspx?FolderID=107
Dubai Education Course Handouts, February 2011
Handouts from the PACS/ICS/ICCS Education Course held in Dubai, 3-5 
February. The handouts are from the ICS speakers only.

http://www.icsoffice.org/Documents/Documents.aspx?DocumentID=897
K Peters, Nerve Rerouting
Friday 4th February 2011
International Continence Society

36-Month Update
[] Recently finished 3 year follow-up
[] 7 of 9 returned for follow-up
[] 1 (37 yo male) no change in symptoms
[] 2 subjects not returning considered non-responders
[] Bowels improved 5/7 on GRA
[] Bladder improved 4/7 on GRA
[] Incontinence still problem in most
[] 6/7 would undergo surgery again
[] Success?  Not Sure

36-Month Catheterization
[] Baseline all subjects were on clean intermittent catheterization
[] 36-months: 4 (5) of 7 off catheterization
  - One subjects mother had her restart ISC prior to 36-month visit 
due to a single UTI
  C Patient is sexually active teen with a PVR<50cc
  - Now off ISC
[] 1 subject catheterizes only 1 x/day
[] 1 subject (37 year old male) had no change in bladder from surgery 
and on ISC

Voiding
Void Diary
[] Baseline 2/9 voided some
  C Mean voided volume 27cc
[] 36-month 6/7 voided (without scratching)
  - Mean voided volume 156cc
Uroflow-36 Month n=6 (37 yo male could not void)
[] Mean voided volume: 248 cc (without scratching)
[] Mean PVR:  93 cc
[] Voiding efficiency:  73%

Voiding Pattern at 36 Months
[] 6/7 leak urine, all with stress incontinence
[] 2/7 occasionally start stream by thinking
[] 1/7 no valsalva to void, 4/7 valsalva void greater than 1/2 time 
and 1/7 valsalva void always
[] Urine stream described as: Strong-2, Weak-3 and dribble in 2
[] Daytime continence: 1-dry, 3 occasional leak and 3 frequent leak
[] Sensation of bladder fullness: Yes-7, No-0
[] Improvement in bladder sensation: Yes-4, No-3

3-year Compliance Data (n=7)
[] Median compliance 15.2 ml/cmH20 baseline vs 28.4 ml/cmH20 at 36 
months
[] 3 children had compliance less than 10 at baseline:
  C All normalized at 36 months
    - 7.0  -> 34.3
    - 9.4  -> 21.2
    - 8.3  -> 28.4

3-year Bladder MCC and NDO (n=7)
[] Baseline MCC: Mean=210 cc; Median=200 cc
[] 36-month MCC: Mean=293 cc; Median=316 cc
    *Children are 3-years older
[] Baseline: 4/7 had NDO on UDT
[] 36-month: 1/7 had NDO on UDT*
  C All patients off Antimuscarinics except 1*
    * persistent DO-37 year old male

Reflex
[] By 12 months 7/9 had cutaneous to bladder reflex defined as at 
least a 10 cm/H20 pressure rise with stimulating dermatome on side of 
surgery (range 11-30 cm/H20
[] At 36 months only ONE had reflex remaining and much weaker than 
earlier
[] ? Suppression of reflex by CNS

Adverse Events
[] No new long-term adverse events
[] Stable renal function
[] Stable renal ultrasounds

UPDATE
[] 2009 added Holly Gilmer, MD a pediatric neurosurgeon as part of our 
team
[] Dr. Xiao returned to Beaumont and proctored Dr. Gilmer on the 
rerouting procedure on 4 children with SB
[] Transient weakness, no foot drop
[] 2 subjects had dural leak
[] At 1 year, 2/4 off catheter and meds

2009
Conclusions
[] Neurogenic bladder and bowel remains a significant clinical 
challenge
[] Developed countries with adequate resources can often manage the 
patient with CIC and medications thus preventing significant infections, 
renal failure and death
[] The concept of nerve rerouting to restore bladder and bowel 
function was popularized by CG Xiao from China
[] Successful reinnervation of the bladder and bowel may not only 
improve QOL but also be life-saving in countries where catheterization 
and/or antimuscarinics are not readily available or affordable
[] In the spina bifida population, our pilot trial demonstrated 6/9 
(66%) had clinical improvement at 36 months
[] A risk of lower extremity weakness is evident in that 1/9 subjects 
had a permanent foot-drop
[] No other long-term adverse events were identified
[] Defining clinical success is a difficult challenge in a disease 
state that impacts many aspects of bladder and bowel function
[] In this study, stress incontinence remained a problem, although NDO 
and antimuscarinic use were reduced
[] We feel strongly that multicenter clinical trials are needed to 
determine the utility of nerve rerouting in the neurogenic patient
[] We should better define the ideal patient population, refine the 
surgical procedure, improve the evaluation of the urinary and bowel 
sphincters and assess quality of life

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ФФϷ仡ˡʧķ仡

ߣʸ

BeaumontҽԺФٴ鸺K. Peters͸¶
꣬ʣһߴڷ䣬ԶǰӴʧ
淴仡ФʧˣӴȲˡ

20108£ٴһʽн۲쵽仡
ΪɹҪ־ƣѶôǳɹѡɹ
Ϊ̼Ƥôȷʵھ
ˡ̬ȵͬרңΨһҲǷ仡
ͬרҶФٴۡФ
νѧͬʡڡԮФҽĹšҲƣ12
ã9е7Ƥ׷䣬֤ؽȷʵˣ
ɼ˲ģФҽӦõõν֧Ф
ġңNIHФڶٴ飬ǽ
Ľ趨ΪҪָꡣ

ФɹҪ־ʿעغϿɵġ淴仡
ھȻʧˣһ𾪡˵ʲô

1. ƷˡФۻФϷ仡
ûˡ仡һ˿¥

2. BeaumontҽԺһѧͼеƤ̼֮
ӳǰ仡Ĵںܿǻ߾ѵγɵ䣬
񾭡񾭷䡣Ф֧ߣfreeway
Ҳ²⣺ַ仡е䣬ʡǶԷʧ
ֱ˵Ľ͡Petersڲ²ⷴʧΪ˷䡱
ǹŪ顣

3. һͳƱФЧ롰仡
ء仡ʧȷ֤һ㡣

4. ûˡ仡Фڲּѻϲ޵
Чֻ˨ϵɽȱ޲Чͣ롰Ф
ͬʱĸôͳһ̶ϻָ˻ߴסֱϵ

5. ˻뼹ϵжϣڡ仡ʧע
ܳɹ¹6Beaumont2˻һɹѾ֤һ
㡣ּ˻ߵĲ֢״ЩƣֻܽΪжЧ

6. ѱͣȴNIHڶ飬ûʼעʧܣ
ΪҪָΪ̼Ƥ˷
Ҳ˵ǴǰδʶҲδФ֪淴仡Ȼ
ʧ١

7. Фδڶʵ顢¶ʧ֤
١ؼ

Цһ

ФФھƽɽڳһϵͭߡ
PetersȻأ
ФйƹФڳ˸ͭߡ
Peters
Ф֤ǹձʹõ绰ͨѶˣФھųɹ
PetersФھ˼ʯͷ
Ѽ¥ˣһǿ޻ָһ¥޷ָ
Ƿɹȷ
Фۿ֤ǹձʹͨѶˣ
PetersȻ״ԭˡͨѶ˵绰ͨѶ
Peters״ʽʱҵͭΪųɹı
־ô죿
PetersۣԴ㣬ӵڶഫͳȽĿż
ЩȱԸͳȽĿżĹңФھܽʡʽ
ҿش󿼹ŷ֡
ФдᣩĽйĻáѧĽ֧
ҡ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ɭɲ

ߣͬϺ

ǰɭĳϮΪ۽㣬ûȷ˵
ձ45ͷ濯Ǻʡί֯Ĺʾɭ桰⽻ְ
ҪˣٴγΪ̳ȵ㻰⡣412գʡί
֯ٿͨᣬɭı͹̡˺ձԱ
¡øɲӱ³ƣʡίƸɭ棬
ʡɲɳ̡ľʩ֮һҲʡϽ˼롢
ɲƶȸĸĻɹšɲɳ̡ƽȫʡ
иɲӱ֣һɵ˾Ȼ
زɲƶȸĸĻɹΪʲôܶ󸯰ܷӰǰһٱ
ԭҲҪʣɭɲ𣿴
ɲԲ㡣

²ż汸ǶһɲĻҪɭûĳϮΪ
޶ۡǰɳϮý屨ƣ廪ѧί
ʿʾѧУ˽ӦɭУڼĵʦ֤ʵԴ
˲飬ɭ汾ûоӳϮһӦʵϣ
˲˵ûϮ廪ѧһûϮļѾ
Ĵ𰸡ǰεӳϮ¼УͨĽǡ
淶֮⣬ȷǳϮ˺ôҲסԡ
г廪ȴܸһƵĽۡΪʲôĿǳϮ
ʱʤȻҲпܺҪ쵼ҡУź
ôûˮƽߵĿԲ󡣼Ȼɭ˶ʿڼĳϮ˵
ȱкͳţѧʱΪõѧλֶΡھͲΪõŪ
ٸʱһʮǰ鴦ԭίĳ
鴦ǰȷɲֵñڵгҪ۵öࡣһ飬
ȻڵְʱΪϼʾ̻ץúýͺɽᡣŪŮ
һٶˡʡί֯ýɭĳϮ
ŵɲӦ۹⿴ˡȫ𱸡Ͷ
ܡ ɭ塰˼ʺáӳϮɭԹںýһ
ֱּĬҲͰˡǲҪʣ֯ʵ˵ûУ
ƭ֯Աɭ岻޵£ҲвšΪ
廪одһƪӦòʲô£㶼˲
ףô˲ţŵ

412ʡί֯ͨɭ⽻ְй 413
գƸɭģѧģǺʵġϸͨ
ѷ֣ɭѡμֱһЦ˵һ־硣ȣѡǰ
ʡίѾȦѡɭ塣ͨƣݡɲɳ̡岿
ʡίУԭ差УƼһ⽻ְɲ
ѡ뵽ȻƼɲѡȻƣ32
35ꣿҲӦƣһϻ򸱴ϣ414պʡί֯
йظ˽ܣʡ쵼ӳԱ3658ˣ35µĽ
58ˡƲ⣬пҲֻ1-3ˣпеֻθְ
ֱſҲ35¸2-5ˡְһ
пֻɭһˡΪְƣҪְ
͸ơţ214ʡί֯ٿɲ
Ƽ170ɲ޼ͶƱɭ115ƱĸɲӦֻи
ϵĸɲܲμӣܴϼ쵼ͼɭƱʵڲ
ߡ̸Ƽ˳нͿ죬߰ٷ֮
ʮĶӦһĸɲݸɲʽĿ
𣿲ʡί֯һ飬Ϯ˶ʿѧλĸɲǸô
ǸΣʵʮǰмίѾ˴𰸡ʡһ߹
г޷ģΪȡ˶ʿѧλмٶ
мί鴦;Ҳͽˡ



ʡί֯ͨɭ⽻ְй

ʱ: 2011-04-13 18:43 Դ: 

Ϣ ȡͨѶԱ򹫳ɣգʡίо˳
ίǡгɭͬ־⽻ְ42գʡί֯ɭ
ͬ־ǰʾһЩýĹעգʡί֯ٿͨ
ᣬ⽻ɭı͹̡
ΪӦѧչԽʽչҪȷȫʡ绻
˳Уȷ쵼ӵƽȽ棬Ը쵼ɲ
רҵɲƫٵ״ʡίоʵʩɲɳ
̡
ݡɲɳ̡岿ʡίУԭ差У
һ⽻ְɲѡ214գʡί֯
ٿɲƼ170ɲ޼ͶƱɭ115Ʊ
鰴ա쵼ɲѡù涨ķΧ80˽˸
̸Ƽ72Ƽɭ档ƼɭڷƼУ
Ʊڵһλ󣬿ֵ˳нͿ죬126˲μ
УɭƱ124ţ124ͬΡڿУμӸ
̸69˾ְͬɭǰʾڣʡί֯ȫ
ʡίίԱͺίԱɭνְʾͬ⡣
ӿɭ˳ǹڼ䣬ί쵼£Ž쵼
һˣȫиɲȺڣʵƽᷢչȡ˽ϺõĹ
ɼ˳еֵطһԤ롢ģϹҵҵ
˽ϴ˾֧롢ũ˾Ҳнϴ
ߣȫʡ򾭼Ŀ꿼˳ǰ17λ

ʡί֯йظ˽ܣʡίɭ⽻ְǻ
ǣһɭ˼ʺáְԸڻ㣬
Աһ𵽻㹤˵Ի㡢Ⱥи顣Ȼᣬ
ȽأҪȽϣûӳڶɭõ
ɲȺϿɡ20096£˳еĽ˴ĴλȫƱѡг
ƼƱɭгڼıֵõ˳
иɲȺձ϶ɭһķչǱʡΪͬôѧ
廪ѧ˶ʿоһרҵ֪ʶʵͶλ
һļԦȫָ֡Эƽʱѧϰǫ̤ʵ
ЩΪ춨˽ϺûνӼıԶ
ڻʵнһɳģɭƸεְ
ʸݡɲƸθɲԭԹ涨͡ʡ
쵼ɲƸа취ڡһ쵼ְƸεһ쵼
ְģӦһ쵼ְһꡱҪɭ˳ίǡ
гʱ䳬1꣬Ƹεְʸɭ⽻
ְƼ졢õȸڶϸִˡɲй
涨ѡγ淶ɭ⽻ΣǺʡʵʩɲɳ̡
ľʩ֮һҲǽϽ˼롢ɲƶȸĸĻɹ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ٱ񲿳ְVSɭг

ߣ

õ¹ٱĳϮ֧Ųڱְһ,ͬй
걨ƼмűԱ,дһƪΪ<¹
>(:xys20110304),̾еѧ׵ķȫͬ.º
ٱ֮ͬɱƺ̫ǿ:һλǸε,ǹҶ߹,
һλǸѧʵ,ûκιְ,ǵҪҲͬ,ӵ"¹¾"
Ҳеͷ.ûһ¶༸,<˿>ֳһƪΪ<Ϯġ
г,ӣ벻>(xys20110412)һ,˵<ձ>45
ͷ濯Ǻʡί֯Ĺʾ:ɭ桰⽻ְ".»תӵĸ
̾:֮ҲˣҪΣ˽","Ϊ˸õ"
<ʲô˼ʺã--ºʡί֯һ⹫>(xys20110414),
ԭιûô,йʡί֯⽫ɭ""ֹǸ,
ϰһõ:Ƹɭ棬ƳһЩڸĸ￪
Ȼ۹⿴,þɳ˺Ͷɲȫ𱸡Ͷܵȳ¾ɹΪ
˲ӱӪõỷ.ѵ˵רҵˮƽ,ֹ"
".ʡί֯Ҳ̫Ŀ.Ⱥھٱ֮Ҳ,Ҫ䳰ȷ,ʵ
̫,ֻܲڸɲϼй,һ
λùĹٱ.

¹Ĺٱ񲿳ĵùͬйɭгĸ̫пɱ.λ,ֶ
,λǰ,ҲĳϮָժ,ֻǹְȴȥԶ,
ǰǶ߹--(¹),֧Ųڱ㶪;(й)ͼԱ(
Թ),֧ŵ,޳,ӹٽ,벻!ѧǰ,
˾޴,˴۽.

βܽΪ"й͵¹鲻ͬ,ѧܾͲȡͬʩ".
鶼ǲͬ,κι,ʲô,ѧ,ֻһ̬,"
鴦",ù鲻ͬΪڻѧܵĽ,ȻǼûϢ,Ҳܵ
.¹ѧһϽ,о͵õ˼ûر--ѧ˵ҫ۵һ,Ƕ
Ĺ,Ϊ.־ҪΪϴ׵й(ë:йӦ
нϴĹ),ԲӦù鲻ͬΪԼڵѧ绤.κνڹ
ͬ,ѧɿ,о,ԳϮ,һ,,ģ·Ĺ,
۴ͳĻ"",ҪѧϴĹ,Ǻѵ.ŵ
ȻѧǶִѧ׵ľ,˿ֻйʮ֮һĵ¹(
ǧ),ӽλ,ǶϸѧĽ.й˿ڽ֮һ,
йʮ,GDPֱ׷,ŵͬ,,,Ҳ,
,˹̹"С,,"ͬһ"噞",!˽Ͷ,
дĽ֮,ѧ緽Ƿд?ٱɭ,ͬĳϮ,ڵ
,йȫһǷֵþ?

йɭɵĻشͬ¹ԹӳϮĽ־˴ķ,
ǹ߲ͬı.ԹƵó¹ԴѧܴĹ:""(ע:ںŷ
Ȩй),йĹ?ҿ"è"ɷ--"ܰè,è,ܴס
Ǻè".ΰ"è"йýͼӰ,Ŀ,˼
оʮ,йר,,,,ֻ͸(Ҳ,йǲ,տ͵
,첻),ҵ,"è"ҲΪѧ:йƼ綪
Ϻ½"о"־,߲оȻ˰ĪоƬĥȥ,"й
о"ĳ½Ϊ"ؾҪھ˼ǰ",Ǿѧ"ܰèè,ܴ
Ǻè";ϺѧУ,ԳϮƣҲҪ,һ"
1988Leibniz",ְ,,ѧ׵Ͷ߼¼.
¶,һλ쵼̬,Ҳһֻè;ɭӳ
Ϯһ,ڳ½,λǰǰʮС,ѾΪҪƸεĺè.浣
İѾýй--"è"ڶԴѧ,,½֮ĺè,ë
ڴ"йӦöнϴĹ"һջ.

й쵼ϴʲ:ڵǰй,һѧܾ¹,洦,Ŷ
һȥ,è,ʧ.˵Ƕ!ֱѧ"ƻ",
Ϯ,,ð֮൱Ȼʹ,ǵľٱҲֻһһҪ:ѧ
Ҫ,ѺЧ.ҪЩ̧ͷ,㶼,Ҫ"ί
ɼίԱ","ѧ淶ίԱ","ѧ罨쵼С"ʲô?

ٻصɭ永.ٱ,ʲô˵û,ʡί֯Ĺ
ʾ:⽻ְ",ѵٱ:"ɭͬ־˼ʺ",:...Ϊ
˲ӱӪõỷ.ĳϮɵг,̫.
ȥ,йѧɹ:"(ɹ),(ɹ)",Ⱥè,һ׽,
ʲô,,˵þһ,йȽҽԶ"㷢,ģ",
"㴴,"ľ.κٵ"йҪΪ͹",ֻ"ˮ,
л".

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ֻʵ
Ϊʲôɡг

ߣKEN

ɭ¿ֻҪ4¼ڳΪ
ɭ桰Ρˡ

ʱ˳

1.20096£ɭܹƪĶԡ
ڼֵķزҵľԡƸĸ2002
5˷ġ۷زҵľĿӪ
̽֡ڶ͡ƪȻɭ˶ʿѧλġ

2.ɳϮý屨ƣ廪ѧ˽Ӧɭ
ĵʦ֤ʵں˲飻ɭ汾ûоӳϮһӦ

3.110¹ȥһûм廪ѧκκ˲Ľչ
ûпɭԴɵκλӦ

4.201145ձͷ棬˺ʡί֯Ĺʾɭ桰
ְ

*ǻĻ֮Աȵǣ201131գĳϮ
ŵĵ¹ڰַȥְ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

廪ѧĲӦɭȷϵϮ

ߣ廪

20096£廪ѧʾ˲ɭ泭Ϯ¼
(http://cd.qq.com/a/20090626/000342.htm)궼ȥˣٳٲ
ڵΪɭȷϵϮ 룺޳
Ϯ廪ѧһڵһʱý幫֤ܵס

̾¹ϮйϮ٣

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

츸³δѡոġõ誽ڵַӡ

ߣط

ո414˿Ϸ¡õ誽ڵַӡ
¼ơ̹СԼӡõ誡õ誡
ҪΪõƽ·ת̡˽Ķ߿ɲο414˿

ĵĺ˼ǣһʼոҲͰͨСһŭ
ͷԣƣڡϸµĽ̻塱ڡƼ
աڵġġѧᡰ˼⡱ˣոٹ
ҲӦѧϰ

ոһõ־Ͼ޴ġϴ񡱣һ
£źҵ޶ۣжոûΪʲô
֡޴˼ת䡱ôѧϰʵҪѰҴٳ
˼תĶֻ㣺

1. 323CCTVķ̸УСΪ̽ʱ
ĳ֡ʧ󡱣ûпڶԸרҵ֪ʶ¹ڶ
⡣ոҲΪ⣬һʼڵߵģ

2. ½½ͨ;ʧ󣬲һ
Ǳһ̬һЩ̽뷢ЩӣȻ
ȥʾˡרҵɣڲѧ
Сոⷬͺ󣬡ȫϿˡ˾
һΡ

ոΪⱻںס𣿻飬¶β
˵ԭǻոġࡱǺãһϸһ
ڵġϵۡǷո˼شתӰ

1.õ323CCTV̸ĿеĴֻǷˡûп
Ըרҵ֪ʶġʧ󡱣ûйΪҩα绤

ҩΰеյĵӽĿУȷʵֻˡɱԭ
ûй绤˵Ϊ⺢ӲӦ̡ǿķ

õŮʱΪĶί
ʹ࣬вʵʱȴڸٸǰٵһͬĶ

עеġί֣ʲôίںͼ߷̸
˽һ

һٵĹ̵Уٶȥһһѧ
ĹǷǳģҪﵽһˮ׼ĻͲϲ¡ϲ
顣ܶٵҲҽܣٵĹйʹࡢ
йΪҪ˵ġ    

ɱԭĻͳΪЦﲻֻۣ˵һʵ
ͥ죬õԷѧҵݣ̨ķؽ
Լʾ⺢ʵǿˡġӶɹ㷺
Ӱ죻ͬʱҲɰʾ·Ժ˰ͷᷢɣǰSBڶ
ҵרҺסˡЩרҵʿʾã
ѧң᲻ãȻҪΪ֮˵
ʲô˵䱾⣬ҪΪרҵӰΪҩεĿ
׵ġºȻܡί˵ĲȥΪ绤İֻ
ҵķûдģֻûע⵱ʱﾳû
пڶԸרҵ֪ʶȥģУ

̸ڵǸûпڶԸרҵ֪ʶġʧ󡱡
ڷ̸Ŀǲ˺ܶƫרҵ㣬޷⣿
Ƿ񶨵ġ෴ίľԵٶɱˡۣ˵ڹ
ǳͨ׶̸ݵְ棬ФӥѾμФ
ӥͣһǶȿһѧҵĹףǽ
ѧƽ׶Աͨ⣬Ըõػ
⡣һ㿴õǸϸѧҡԣڶ
ߵԭ򣬲ûЩרҵ֪ʶǡǡ෴̫͸ˡ

2.ڲѧвС⡣

ҲھܾϴҪɣֻǿʶı֡
вûҲҪʲôжĶΪʲô
ٸӣһѧңĳµӣ޷
ΪУҿֱ׳ָǸƭ
ӡЩֻĻʶ漴ɽжϡʱգõ誽ڲͬ
ĳϷȥ۵Ļһ׶ûниΡѶ
ѧЩ署׸ʲô

3.ڲϽܼߵĲɷãԻɱ˷⣬
Ǳܿʵ⣬ϸߣѹˡһЩ

һΪǵĺѧɱ¾ΪǵϽֲ
ײɱĲһΪͥҪ20ȴһǣΪ
ҵоúܶ棬ǺǵˣҵоӦܵأ
ΪңΪᡣ

ЩθУϲɺأҩΰô
оۣô棿ίɱˡ˵ҶӦù
ôίɱ˵Σ𣿿ҩжίǰѧ
ѧѹ˵ѹҲҪǸ߿ǰ¶ڶˣ
ҩǼҾϴѧʱгҵȻԼ⻹ɱˣ
ЩһעҪڡūӰµСô죿취
ί˭Ƿӣ

 ǶҵķŭʵǶ˵Ϊŭ͹۵ؽ
ķŭһȻУصСǣǵķŭѾ
ǵԺκοռ䣿ݵñ˵뻰

Ҳ֪εóŭ۵ģʵϣҩ֮
ǰҲ֪飬ɲûл۶󹫷ߡڵķŭ󲿷Թ
ýԵıԼΪһרҵ޳ܱ绤
ŭĲˣõ誣˸ɵǺڰ׷飬ɱ˳
򵥲̼һǵһ죬ڸɵȴͼ˺ڰ
ֵ飬ǵ̣£㻹ʲôʸҪǵ
ռǵĺ˵˵뻰

ԲѶáĸ롣֪ʲôҵĸ
ǷŭǶƶ˳̶ȵһͬ飬ܵļҽ
кѬƶһźҳ˵˶ԣµĲʵƶ
ϵƶ

Բڣǳáʧáԭ
ƶǶŤεһַӦͬ飬ǲ顣

ͷ룬ҲõԼҩķˮƽĵ£
ôˮƽķΪʲôҪ˷Ϊ
ѧҪԭֻһǾͨڵĻˮƽ
ͼﵽɸ˵Ŀġո粻ңΪƷеһ

Ŀ£ڵ˼¿ɷΪɣһ˵شʹ¼
ɻͬļ⣬ԣ翨ǷӦ̨ȡ
εҩ¼õΪαרҵı֣ȴ⵽ͬʱ
ҵĵʹ춫ȣ˵Ѿ񹲷ˡ
ĳ˶õ誽ڵ̬ȣ츸³δѡֻҪ
һ첻ϴڵַͲֹ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

֢ߡңΰ֮ӣ

ߣ

ңԳйΨһŵѡˣԳѧţԱسԼΪ
ĳĳڿˣԳNatureˣٳnatureȫֻиλ
֮Լǹtop10ԱĳĳڿίxxxXX

Ե˵ۣԱۣۣίۡණΪ
ڣѧɾ͵ȵȵΨһ׼...ǲԼģԼH
ָһἰͼ˵ţ˴⣬ţţֻagainˣ
Աί

ѵĴ˼˾Դ˼д

ã
Ҫҵ
1ڹ״ջЧӦѧˮ·
ˮ繫Ϊһµˮо򣬰ҵڣ
ıôӽ3Σ
2չһµĹ׷ѧ뷽о1996
ŵйһýо
3ڹϷ˵һƪѧӦ۵ģѧӦ
˹ʳϵĵԹ
4˽ѧӦѧӦѧ;

ã
Ҫѧ
1996.3ŵѧйһλýѧߣҲĿ
ǰΨһһλ;ǰŵʷϵڶıߣ;
2001.9ĿƼ¼Whos Who in Science and 
Engineeringʿѧ빤ˣ
2001.4, ѧѧ125Ա֤
2001.4. ѧѧMember-in-good-standing[Ա]ƺţ
2002.5ӢʴģIBCΪ2002缶ѧҡ
2002.8IBCΪǧλѧҡ
2002.9IBCΪ21ǧλܳѧߡ
2003.1IBCΪ2003ȹѧˡ
2005.11, ٴĿƼ¼Whos Who in Science and 
Engineering
2006.2, Whos Who in Asia()Who Who in the 
World()
2006.7, ʶѧԺ֮һŷ޿ѧԺAcademia EuropaeaЧ

2006.10, Whos Who of Emerging LeadersɳеĿѧ;
2007.3, IBCΪʮһͽܳѧҡ
2007.4,,IBCΪ2007ȹʼѧҡ
2007.6, IBCΪ2007100λѧҡ ;
2008.6, IBCΪ2008/20092000λܳѧҡ
2008.12, IBC 21ͳɾͽ


ԭǹWho is whoҲshock~~~~

𼱣гϢλƲļɣ

http://blog.sciencenet.cn/home.php?mod=space&uid=1259&do=blog&id=412298

һϣ󣬸ףĸֻԶһᣬ
׿ˣ˵ѾˣҸΣʵ벻
ʲô취ҡ
ֻ꣬۵ҿˡ˵ӢŴѧԼɪ
ойʷа취
ע3꣬3꣡ʱ3꣡

ڸлظ

ظ(2011-4-8 12:45)ë󶫺һηˣĶ
ӡ 
ظ(2011-4-16 09:17)ǵġ
ʵĴλˣѧı༭϶֪ҵġ 


shockˣ˲ǰΪû廪߶廪أ
ԭݣɶĲǸΰ֮ŵˣ
ڵİ

ע⣡19703꣬

ʱëϯ77꣬ϯ74ʱӣ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ԡ˼ƫѧΥݲ

ߣmoonzy

Ҫƹ԰˼ƫڵʮѧȡ
νѧҵ̡ƶȡҾһ£ΪЩѧڴѧ
еȺеĺܶ˱ǺױԵģǽл̲ṩ
ҪİʵҲһֹģٿǸоûΪһЩԭ
ڡȻھ忪չʱҪעⷽʽġ

ϻԾýʱǲôץסһ˼ƫ
£Ϊⲿѧһ¾ͳˡɱǵĸԡǵ
˼롱ҺӴЩ˵ġԡ͡˼롱ǴУ
һ¾ͱɱ͡ˡ

ѧУġɱ͡ЩʱȻ̧ˡУ
Ԫᳫġݲİ̾ػšǲ֪Ƿ
֪ԪҲԡУΪ3¾ͱҵı
ѧźءϵѧ϶ԵʱԪ࣬ʵ
Уİ׻˶ʮֲд¼̱ķʽ
ѧźؾΪƪУ£ʵûУĴ
Ϻıֽ϶ġ꿪ԭǣ

ѧźŴͨھ޸֮ҥԣ𻵱У
ѧ̵µʮһѧ˲

ıͬԭ򿪳ѧЩʱ͡ԡ
˼롱ˡ

ԣνġݲû޶ȵġ˼ɣ˼ҲҪ
ԵıһܹýĴѧǱѧУ
ʡԼνġ˼롱Ͳǿԡݡ
ġ

οҲֻҪЩѧ̡ѣû˵Ҫѧɡ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ҹҲĲг

ߣŹҫ

裨teaԭȷںҶϳҶɼࡢ
ɹ򷢽֮ˮлݳϣǿԱṲͬ
衱ĲҶַڶž黨Ŀ//ɽ/й
֡ѧCamellia sinensisУCamelliaǡ衱˼
sinensisеġйھҹϷ
ҩ̺ͲũŴͳҽҩĻӣʵΪұ񡱺
ƴա಻òҶҶġ衱

гң˲ɸ˵⣬ƾõʷ
Դڹ㶫ϣҵļ磩ϰһֱҩҲ衱
ҩί˵ҲȲ衱ҩ̡ץҩͨҲᱻ˵
ץ衱衱ʵҽΪȽҩĸ￪Ժ󣬹
ȫӰ쳬˱Ϻǣ衱ĸҲӹ㶫ұȫ
ܰ衢򻨲衢ջ衢ǧպ衢Ĳ衢ඡ衢޲衢
衢β衢ʲ衢衢󳦲裬ȵȣʵۻҡ

˻ҵĲгũҵҽҩҹ̹
ֵȲţһֱȡһֻ۱һֻ۵̬ȣȫط
ǵʩŬѿıƺҩгҲѰµľ
㡱һζؼӴͶ룬һ·̵Ƶءʵ¡޼ɵġ
ġܡϣʹǵϰĪһǡÿһ
˶ѧԭɥʧжԣܶһѵͷԣʱ
пܵɡ㴫ͳĻõ֮ȥ

йĲгٵĶ࣬Ҽٵ١ٻиӵ
ϵˣҪҹǰҲĲгһʮѵġ
ǣǿͨһЩͰҹг״ıߡ

һඡ衣

ඡĻԭȡԴҶIlex latifoliaThumbҶ
ֲձйз֡һֺܺõĹֲй⣬ֲ
ûκطҩҹҩڶĩ
ꡣݸĿصġ«ֲ

ûע⵽ҹŴҽټҩֲĶ
áҹŴȱȷжҩõķЩΪЧҩ
󲿷ֶʵЩ󶾡áļأȽϽӽ͹ʵʡ
ඡҹŴҽбһЩõġҩݸĿ
ؿඡĸǣ˲˯峯ѧ鲻꣬Ϊʱ
©˿ඡ裬ڡݸĿʰšвֲҩüֵ
硢ѪСˡСԣඡʵҹŴ
ҽкٱٴΪҲռʱˡȡ
ҡ֮ǣʱ仹ǼˡζȲ費Զӡඡ
ĳϸ͵90Ժ󡣶ңڿඡ֮ǰûоκ
ѧ֤ȫƾһЩɿʷţϡͿˡ

2001꣬ΪYuerong Liang, Weiyang Ma, Jianliang Lu, Ying Wu
λйߣ˹ڲҶඡ֮ĳɷֱȽо档ǵó
˵ͨĲҶ16ְᣬඡֻ15֡Ҷ
ඡ15.8⣬ඡȻҲάCֻвҶ22.1
ҲȲҶһ롣1995꣬ǭҽרѧ״αÿඡ
60죬ͨ򵰰ףѪصⶨ۲쵽˼õʸı䡣
ζţඡܵж

ֵرָǣҹԱضԿඡⲢһ¡
˿ඡԴǳҡ2007꣬һؼʡףвũڲժӹ
ҶǵؽС١ǣǲժЩҶӸʲ
ôǸң˵ǿඡ衣˵չԪǮһ
Ҹǣⲻǿඡ裬Ƿжֶ
ҵĻԺǾҲûмժνġඡ衱ˡ

ֲеһ֣ᣬصжѾ
ȫ磨ҹֹҩһЩġҶˣȻ
ͨũ壬ֶչΪඡ衱ʵ˴Ŀģ

ڶʲ

ҹļʲгңֱ߰㣬һǴҹŴû
ʲôʲ衣ȻеļʲȴšҽҩĻĻӡ

ҹļʲ˷ˣлصĨһء
1998귢ڱʱġвҩ¼

1992꣬һλƭǮҽڱʱ˸ҩ̣Լ
ļʲ衣ٱʱŮЩʲ֮󣬳˲̶ͬȵж֢
״1998꣬ۻʹ43ɴˣ༲
вҩ Chinese herb nephropathyCHNһơ¹
ձӢġвҩֱΪвҩļ
ڻ߷˸ֲġ

صҽѧѺ˵ѣҹҽҩ
ԹڷϢǵ¼س̶ȡһֱϵ20034£
ԵذעתSARSʱ򣬹ҽҩֲżʵطĸ棬ֹ
ֲľͨľ㡢ɰҩȽ
¼ҪöࡣSARS200461գ
ֹ72ֲҩ˷ָǣҽҩֹ
ֲҩ֮󲻾ãּŪеȨΪҽ
ҩʵ¡νƷľͨġСͼѾ
ɾ˵ֲ任ûصҩҩȥ

ҹļʲгصĹӰ죬ûоҹǿ
ܡҽҩֻ֮һٱ䱾ضҹҵļʲ
ĹηǣƲ£޲裬׷ԾԾ
ءлͳĻʲ衣ӡҲʾ׷
ˡʲ衱ϡйĲгŪ


Ÿĸ￪ŵ뷢չҹѧ鷢벻ı仯ѧ
⣬һЩѧˡƾعƭǮơĹ
вҽҩթġƭӡеġնٻݼ
衱ɡƭӡ׫ġʲ衱ĵ͡

˵˵ն١

ն١ӢԭleptinҹСͤء
ݵסͬķ롣ƭӡұ˵һ
(Leptin)ҩ˾,ȻһԿвҩΪսĿġ
ҵ΢еӢĶˣ׾ٵشҩҵ
ļװ

Leptinԭһֵʼءǵģ
ʳʹлڳɹϸƹϸ΢Щѧʶ
֪ڹ˵ĿУɹϸѹͷƹϸѶ
ĹȥƵأleptin֬ʱ򣬴̼֬֬
̫ʱְ֬ĵͿά
صáȾɫϵĳƬϷһͻ䣬ʹleptin
֬ǵл˾ͻᷢ֡ƿԲֵؽ
ͷֵġءСʵ֤С֬賤ʱעµ
leptinСع鵽ء1994꣬˷մѧ
Jeffrey M. Friedman״δʵСϷleptin

Ѳleptin167ְγɵĵʡҪڰ
ɫ֬֯кϳɵġ֮⣬ɫ̡̥֬֯ѳθ
Ƥϸ衢Դ塢ΣҲܺϳleptinleptinĵ
ʽṹܸӣĿǰֻͨʣвܽ˹ϳɡּ
ֻڶڴڣֲûĵʼءʶͿ
жϳνնٻݼʲ衱ȫǲű߼ʵĹ

ĿǰΪֹΪṩźšһȵأ
һleptinڸ˵пܵźǣȵطڹ
򲡡ƵģleptinҲĸΪṩ
ţ

һѭleptin֬ȡ

ڶleptinϵͳѪŨȳȡ

еleptinġ

ġλڲԵleptinơ

ҲоָķȵغleptinĹͬþġ
оָleptinĻϵͳеTϸԾġ
һЩʶνնٻݼʲ衱滹Ǽ٣Ҫرļ
Ͳ鿼Ϳȷжˡֵرָǣ1999꣬ҽѧ
`the Journal of the American Medical AssociationJAMA͡
ӢҽѧѧThe New England Journal of Medicineֱ𷢱ٴʹ
leptinʵĹ۲챨棬ԼͬصóˡʧĽۡʹ
leptinлĻƱԭҪӵöࡣڴleptin
ġݼʡǷɿӦòһжˡ

Ϊ˰չʾø͸ǲԡնٻݼʲ衱䷽
һԵĽ

1ѥҶ(Gymnema Sylvestre) ݳƣԡЧǷݣ赲
Ƿݼߵۺʳе̼ˮ

ʵģ

ӡвյChhindwaraһϡֲӡ
ʹҩݵʷѾ2000ꡣӡȳΪӢֳصʱӢ
ֲݽǲݡ˳ҩ֮ͷǲ
Сնٻݼʲ衱Ͻܾȡġǡ
ܡֵעǣǱϡֲӡȵĲѾߣ
طûֲԣҩҩҪȻ
ҩݻƻ˵ͷǵζǣȱۺо
ҽҩѧ绹֪Ĳ٣ҩüֵӡ
ĵˣҲѾʹֲǡԣҽѧʹ
Ϊ򲡻ߡǡоȤȫͨԼľ
־ȥǣòųѾϡֲľǲݡ

2õ廨裨Rrugosa TeaӢķлĴ󡣺tea
ǺҼȥġݳƣζ𣬿Լ³´лڶ
ųЧȽԡ

ʵǣ

ԭձĺѣձֽɺһֹ
ֲձûнҩļءԼҹġִҽĲã
ҽҲҽۣжϳÿֻ֮Ҳ
Žֲҩġ

3Ҷ(Tilia Europaea)ǴҶʣTilia CordataСҶ
(Tilia Platyphyllos)ӽõһֲõЧ
ǣΪ׳ӣԣ˲ϲֲ
նٻݼʲ衱䷽ġˡΪСֽ֬
Чڷų,񾭣˯ߵЧ˵ûݡ

4Ƭ(Lemon)նٻݼʲ衱䷽ġˡΪ
ˮڶصųϴθֽ֬⡱ʵ
񾭳ʳõˮǷ߱ĹЧÿ˶ͨ
Ӫֵ֮⣬ʻҩüֵһʵķζ滺
ԵãһǵPHֵ֭пá֮⣬й
ʵ˵ûݡ

5ٻƹƤ(Garcina Cambogia)նٻݼʲ衱䷽
ˡƣֲĹƤ̼ˮﱻת򴢴Ϊ֬
ʵٻƹǰĴ˵ġɽ񡱣Ϸ˽
ˮгԭϼİȺʳƤʳ
ƤֶϺȻɫȾϡ1990˴ֹƤз
ǻᣨHydroxycitric acidʵоͶоǻ
дٽ֬лáǣ1998˫äٴԱʵ
ʾǻԼЧ

6(Guarana)һԵֲʵֽСȡ
ͨȸ޾FDAΪ
һΪȫʳƷGRAS2001꣬˷оƣ
ʹװȽϷ֣мơǣ20065·
Ʒۡնٻݼʲ衱䷽ġˡ˵
ӦճĻҩѧӪѧҵо
ȫմߡ

7(Chromium Picolinate)ȫС़һ
ʳԸȱ档ǣȱ˼亱ҩѧ
ʳǵ֢̰ʳ֢߿ʳΪ
Ԫؿȵطڡ2001о֤ʵЧڡ2003
꣬ӢʳƷ׼ַͨƣ۸°áȰӢˣҪ
۸ʳնٻݼʲ衱䷽ġˡ˵
Э֬Ƿݡ̼ˮＰʵĴлܡȻпɣ
ûй˼ǰоɹ

8׿(Chitosan) ֽСǾǡֹѪ2007ǰ
˷оΪмЧ2007꣬밲οжԱо
Ժ֣׿ؼ밲οûв졣ɼļЧʵ
նٻݼʲ衱䷽ġˡ˵ܡЧʳȡ֬ʣ
θǡ֬գ֬ʽѪҺϵͳڡ˵ݡ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

ҩעš ŷޣ
רҩ̻Σ ⻹˫Ŭ

2011-04-15

 ̼ ʵϰ ɯ ½ 

    ҩŷ١գ㤵ıⲻϳŷ޸
ýҪϡԭŷ2004̨ ͳֲҩעָ
йҵֲҩҵ 2011 4 30ǰעᣬ
ŷ˾ۡĿǰйȻûһҩҵעᡣζŴ5
1ŷڿҩԡʳƷͱƷʽ󣬼 
ҩŷ޼Ҫôȫ𡱣Ҫôȫת¡ʹ


    ҩŷӡ֢֮᾿Ķ֮ںδ
߲ɷйҽҩƷ̻ҩ

1Ϊγٳٲע᣿
עɱ ṩ֤

    ܣҪŷ˵עᣬ辭ύϡŷ˲
ϡҩЧٴ顱裬ڵһУҵṩŷ˵
15ҩʷ֤עӲżйҵ

    ˵ܶҵתƵĹʧǰϣ
ó֤15ҩʷ֤ݡ ⣬ҹгҩʳƷ
ƷҩƷŷۣҲӰ15ҩʷĻáҵŬ
ϵŷҩϿͻǳ߲֤￴ϵͻĹ
ȷʵƴ󣬵йҵڻŬУ

    ⣬ŷעĸ߳ɱҲúܶҵȴעһҩƷĳɱ
80100򣬶ÿҵȻֹһҩͶ롢ڴԼ8
10ꡣҩҵ޹˾óײĹԱܣ٢ǹ˾
ƣŷҲõ˶˹һŷ˳Աĳϣ ǵĲ
ƷϺãעѶеȣŷ޵עȷʵЩ
ˣﻹǹйҵץסŷг ϾҽӰ죬
ҽĻкô

2Ƿҩ
ҽҩͻѽ

    ŷֲҩг¹Ƶоʹֲҩ
ҡ ǵҩǵǴͳҽø 
˵йҩʹãŷϲһֲҩҩЧٴ
УҩЧܺúҲײɼҩԸӡҽ
кŨѧζͬһֲ֢Ĳͬߣҽݲ˵ʿ
ͬķӣҽ̫ͬΪҪִѧľ׼һһ


    ڵ¹ÿг200ҽйгҩڵ¹Ȼδõ
ϿɡҪһǣ¹ҩ涨ͽҽﾫ
ţơߵҩһӴˡ˵ҹгҩŷ޵гͶ
ݶ࣬ʹҲ༯ŷ޻ȦǶǵĹгȽϺã
ĻͬУձгҩҲʹá

3Ƿлأ
ιҽ

    гҩĴŷ˵¼ܣҹҩҵĳܳǲ
ġ⣬ΪҽĻǵ֮˽
ֲرǿļԱȡоҽЧҲǺ
õ취Ҹ˵ϣÿҵԼгҩ
ҩƷƹϻһЩȻܵĽйҵŷ
ҲӰ죬Ǻܿܳҽҩľ桱ָгҩ޷ʹ
ãЩгҩĻֻƬҩƷ棬Ч϶
ۿۡ⣬ŷн10ҽҵߣǵĹҲһΣ
ԣΪŷҲӦߵ￴ ֹ
Ҫ˫ĻŬϣͨó֯˫̸ŷ˽д̣
ӡȵֲҩȽϷĹŷ̸Уȡ˫Ӯ4
30ٽڵĵǷ񻹻תرʾһж
δ֪

    ڽרʱʾҩŷޱʹڿп޵ıԵλ
Լ˳ŷгҲкܴӰ졣


߶֪ҩҵ
ǰֹۣתг

    ʵŷ޹涨̨7ҩҵȫŬעᣬǰд
ųƣذѪͨҩಿ飬ҲͨŷGMP
֤ҩҩҵ ӢͳҩƷעŷˣӢҩƷGMP
֤ĿݷȡɽŨҲõ䵱Ԥͨ
ҵǷп430ǰɡƱŤתƣ߷ֱߣ
ʧ

    ǰעɹݷƺ̬Ҳʡµݷ
ȵĹóײţһԱ͸¶ǰ칫˾ٿŷע
ۻᣬزŽǢĿǰûеõʵԵĽչ˾
2009ġرС顱רŸҩŷעṤġ

    ۼ430յĽֹڽߣݷȻδɹעᣬ
С齫ȥδӣǷӦԤԱʾ ӦûбĴ㡱
вϢǱյģûв빤Ĳͬ¶Ǻ
ݽܣҩŷע걨ڲ̶ݷ
ҵĳڶǳ˳Ա߷ΪŷҩַΪ
ҩƷеĳɷе࣬Բߡ߶Խɡ 

    µǣרŸС绰һֱ˽

    ܹעҵ֮⣬ҲһЩҩҵСõͷ
г˳ŷޣгܵЩҩҵĴʡ
ҩ޹˾ܾԼ߳,ڶг,ŷгķսϴ
гżϵͣҶҩܶȸߣݼ˽⣬ĿǰĴҩ
ҵѾгڶǵ

ŷҩ滷һֱ
ѧŷҩ

    ŷ޵ҩ滷ΣǷܵŷڵĻӭߵ绰
˰йǵҩٲŮʿ͸¶ҩŷʵһֱ
ڱѹƵ״̬滷⣬ԼйǾӪ15ƽС꣬Ҫ
Ļѧͻ˵⣬ÿµǿάơ

    ŮʿΪĿǰҩŷٵҪ㣺1ҩΪҩƷ
ҽҩг2гҩװ˵ܱιܣ3ӡ
ƵȲɻȱĳҩ򡰶ԡֹۣҩΪ
ȫΣֹʹЧۿۣ4Ϊֱ
ƹҩҽʦʦȻ٣β룻5ŷ޵
Ӣͱʱȵط漰ҩҽ¹Ӱҩһλ
ѧ7йѧ߼ߣܶѧ˻ǻѡҩ
йǵҩҩľҪ͵С
Ϊ±⡣˵ҩӢͺҵ
滷Ϊ룬ҩʳƷۣӢмұȽϴ
ҩ꣬лŹ˾Ӣ70ҩЩ
һ㰲1~2ҽĺңҽݲ֢ҩ
ڵҩץҩںݲȫͳҽ3000ңֻ
ģҩ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

Фս

׿
2011/04/15걨

Ѷ Źӡ˵ĻпƼѧФͷ
󣬽նԼûФϷ仡Ĺ
ЧʾڽٿᣬܡФʵʩ顣Դˣӻ
ӦФĲѱ֤Ǽٵġ˫ԣҪٶȽ
ζ

ڱ5ºФͷţ317չҡФԼԼ
ûûνʮˡˡҥ
̰ϸҽͷһЩⲡŻظϺҹ

Ф΢ҲһֱФϷ仡ĹЧ֪ͨң
ġФĿ43ʼղˡѿʼˣһ
ѿչФĴѧҽԺдţܸФЧ
Ϊ0%²СòʽȫʵФ˵Ч
϶һ﴿ҥݡ˵ĽйĻá

ФڽٿФϷ仡дᣬܽ
ФʵʩйչФ1510
λФֳͬʱݻһɿ֯
ҽ顱÷ᡰǩ˽Э顱

ӶԴ˻ӦƣФǼģѱ֤
ٵġڡǩ˽Э顱˵˷дᣬǴ
ģҼġ

Фڲת£оٷԲϣָӡ
ԡԶ߲߿ӢΪڡʾνϮǳ
ˣѳҲͨ;Ϯý˵

ϣ˫ķ˿Ҳִһʣ˵֧߱˴˴ǹལӵ֧
߳Фˡҽѧ硢ѧ硢ɽһ־硱Ф֧
Ʒǡαʿƻġ

(XYS20110417)

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

һΪ˰޷˿վĹ˽˿վĶ̬ؿ
˿ʼбxys@yahoogroups.com

ʼбÿ췢һ˿վ¸µϣÿµ׷һÿ
Ŀ¼ʼбĶμ롰˿֮ѡ
ʼбxys_friends@yahoogroups.com

ù䶩ġù䣬ܿ޷յ
Ƽ䣺yahoo.com, hotmail.com, gmail.com

ġ˿ʼбĵ䷢һհż

xys-subscribe@yahoogroups.com 

塢ͣ˿ʼбͣ䷢һհż

xys-unsubscribe@yahoogroups.com 

Ͷxinyusi@yahoo.comôıļͶ塣

˿(www.xys.org)(xys5.dxiong.com)(www.xinyusi.info)(xys2.dropin.org)

